How should I manage a patient with epilepsy who is currently using cannabis and appears intoxicated (sluggish eyes) during the visit?

Management of Epilepsy Patient with Cannabis Use and Acute Intoxication

Address the acute intoxication first by assessing cognitive function rather than waiting for a specific timeframe, then evaluate for cannabis withdrawal syndrome versus cannabinoid hyperemesis syndrome, and finally counsel on cannabis cessation given the unclear effects on seizure control.

Immediate Assessment of Acute Intoxication

The patient's cognitive abilities—not a predetermined observation period—should determine when you can proceed with meaningful clinical assessment. 1

• Sluggish eyes during the visit indicate acute cannabis intoxication, which manifests as dry or red eyes, dry mouth, and potential cognitive or psychomotor impairment 1
• Assess the patient's orientation, memory, and decision-making capacity through direct cognitive testing rather than relying on a fixed blood level or time interval 1
• Document the timing of last cannabis use, as acute intoxication typically resolves within hours but can impair the validity of your epilepsy assessment 1

Distinguish Between Two Cannabis-Related Syndromes

Cannabis Withdrawal Syndrome (CWS)

• Occurs after stopping cannabis use, with symptom onset 24-72 hours after cessation 2
• Presents with irritability, anxiety, insomnia, decreased appetite, restlessness, and abdominal pain 2
• Patients consuming >1.5 g/day of inhaled cannabis or using >2-3 times daily are at highest risk 2

Cannabinoid Hyperemesis Syndrome (CHS)

• Occurs during active chronic cannabis use (≥4 times/week for >1 year) 2
• Characterized by stereotypical episodic vomiting ≥3 times annually with compulsive hot-water bathing behavior in 44-71% of cases 2
• Requires complete cannabis cessation for at least 6 months for symptom resolution 2

Laboratory Testing for Epilepsy Patients

Obtain serum glucose and sodium levels, as these are the most frequent metabolic abnormalities in patients with seizures and are occasionally unsuspected on history and physical examination. 1

• A pregnancy test is mandatory if the patient is a woman of childbearing age, as this affects antiepileptic drug selection and disposition 1
• Urine drug screening for cannabis is a consideration but does not directly change acute management in an alert, cooperative patient with known cannabis use 1
• Consider checking antiepileptic drug levels if the patient is on chronic therapy, as cannabis may affect compliance 3

Cannabis Effects on Seizure Control

The evidence on cannabis effects on epilepsy is inconclusive and potentially bidirectional—some cannabinoids may have antiepileptic effects while others could lower the seizure threshold. 3

• Animal and human research shows that marijuana's effects on seizure activity are inconclusive, with some evidence suggesting cannabidiol (CBD) may have antiepileptic effects specific to partial or tonic-clonic seizures 3
• In some animal models, marijuana or its constituents can lower the seizure threshold, meaning cannabis use or withdrawal could potentially trigger seizures in susceptible patients 3
• Marijuana use can transiently impair short-term memory and increase noncompliance with antiepileptic drugs, similar to alcohol 3

Management Algorithm

If Patient Shows Signs of Acute Intoxication Only:

1. Assess cognitive function directly rather than waiting for a predetermined time period 1
2. Defer complex epilepsy management decisions until the patient demonstrates appropriate cognition and can participate meaningfully 1
3. Provide a quiet environment and allow time for intoxication to resolve naturally 2

If Patient Has Cannabis Withdrawal Symptoms:

1. Ondansetron may be tried for nausea, though efficacy is often limited 2
2. Loperamide for diarrhea and gastrointestinal distress 2
3. Avoid opioids entirely as they worsen nausea and carry addiction risk 2
4. Consider referral to addiction medicine or psychiatry for severe withdrawal, co-occurring psychiatric disorders, or lack of response to brief counseling 2

If Patient Has Cannabinoid Hyperemesis Syndrome:

1. First-line acute treatment: lorazepam 0.5-2 mg IV or PO every 4-6 hours 2
2. Second-line: haloperidol or droperidol if benzodiazepines are insufficient 2
3. Topical capsaicin 0.1% cream to the abdomen for adjunctive symptom relief 2
4. Never use opioids as they exacerbate nausea and do not address the underlying pathophysiology 2

Cannabis Cessation Counseling

Provide cannabis cessation counseling as the only definitive approach to prevent CHS recurrence, and counsel that the effects of cannabis on epilepsy remain unclear with potential risks. 2, 3

• A brief motivational intervention (single 5-30 minute session with individualized feedback) improves cessation outcomes 2
• Inform the patient that cannabis users have more than twice the risk of motor vehicle accidents compared to non-users 2
• Approximately 10% of adults with chronic cannabis use develop cannabis use disorder 2
• Complete cessation requires at least 6 months for CHS symptom resolution if present 2

Disposition Planning

Consider inpatient admission for patients with multiple seizures, significant medical or psychiatric comorbidities, or severe withdrawal symptoms. 4

• Arrange psychiatric or addiction medicine consultation for evaluation and long-term planning for cannabis abstinence 4
• Connect the patient with addiction treatment resources and provide education about risks of continued use 4
• Document the discussion about cannabis effects on seizure control and the recommendation for cessation in the medical record 3

Common Pitfalls to Avoid

• Do not wait for a specific "sober" timeframe—assess cognitive function directly instead 1
• Do not prescribe opioids for any cannabis-related symptoms as they worsen outcomes 2
• Do not assume cannabis is therapeutic for this patient's epilepsy—the evidence is inconclusive and there are potential risks 3
• Do not overlook the possibility of medication noncompliance related to cannabis-induced memory impairment 3